MarketMoodz
IYH — iShares U.S. Healthcare ETF
Is IYH overbought or oversold? Here is the current MarketMoodz read.
iShares U.S. Healthcare ETF (IYH) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The ETF name last closed at $71.67. The rating moved from Overbought to Neutral on August 18, 2026.
- Public ratingNeutral (as of August 19, 2026)
- Last close$71.67
- Last changeMoved from Overbought to Neutral on August 18, 2026
- SectorETF
AI analysis
iShares U.S. Healthcare ETF (IYH) provides broad exposure to U.S. healthcare equities with defensive demand drivers and secular growth from demographics and medical innovation. Near-term performance may be muted as market flows favor cyclicals and higher yields, while longer-term fundamentals remain supportive.
Key factors
- Broad, defensive exposure to U.S. healthcare equities including large-cap pharmaceuticals, providers, and biotech which supports steady inflows in volatile markets
- Sector fundamentals: inelastic demand for healthcare services and aging demographics provide secular growth tailwinds over the medium term
- Diversification within the healthcare complex reduces single-name risk relative to active biotech allocations
- Interest-rate sensitivity: long-duration biotech and growth-oriented healthcare names can be valuation-sensitive to shifts in long-term yields
- Market positioning: recent rotation into cyclicals and higher long-term yields could limit near-term ETF performance versus cyclically exposed sectors
- ETF characteristics (liquidity, low tracking error typical for iShares): makes IYH efficient for sector exposure and rebalancing
Risks
- Macro-driven rotation: rising long-term yields and flows into fixed income or cyclicals could pressure defensive and growth-sensitive healthcare holdings
- Regulatory and policy risk: drug pricing reforms, patent / Medicare policy changes or increased legislative scrutiny could hurt major constituents
- Biotech-specific event risk: clinical trial failures, FDA setbacks or binary news for smaller-cap holdings can drive sudden downside
- Concentration risk: large-cap pharmaceutical names can dominate the ETF and produce idiosyncratic volatility if one or more components disappoint
- Headline-driven volatility: elevated potential for spikes in realized volatility and options-market repricing could create asymmetric downside
- Geopolitical or macro shocks that compress risk assets generally could reduce demand for equity ETFs, including sector exposures
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for IYH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.